What is Genmab A/s share price today?

Genmab A/s (GMAB) share price today is {{live_price}}.

Can Indians buy Genmab A/s shares?

Yes, Indians can invest in the Genmab A/s (GMAB) from India. With INDmoney, you can buy Genmab A/s at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Genmab A/s at zero transaction cost.

How can I buy Genmab A/s shares from India?

It is very easy to buy Genmab A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Genmab A/s be purchased?

Yes, you can buy fractional shares of Genmab A/s with INDmoney app.

What are the documents required to start investing in Genmab A/s stocks?

To start investing in Genmab A/s, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Genmab A/s

Today’s highest price of Genmab A/s (GMAB) is {{1_rba_end}}. Today’s lowest price of Genmab A/s (GMAB) is {{1_rba_st}}.

What is today's market capitalisation of Genmab A/s

Today's market capitalisation of Genmab A/s GMAB is 17.6B

What is the 52 Week High and Low Range of Genmab A/s

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Genmab A/s is down from its 52 Week High?

Genmab A/s (GMAB) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Genmab A/s is up from its 52 Week low?

Genmab A/s (GMAB) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Genmab A/s?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Genmab A/s

Dr. Jan G.J. van de Winkel Ph.D. is the current Chief Executive Officer (CEO) of Genmab A/s.

Home>
US Stocks>
Genmab A/s

Genmab A/s (GMAB)

$27.52

-0.17

(-0.61%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

$27.47
$27.89
$27.52
0.2%
Downside
Day's Volatility :1.54%
Upside
1.34%
$24.53
$38.80
$27.52
10.86%
Downside
52 Weeks Volatility :36.78%
Upside
29.07%

Returns

Period	Genmab A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.43%	5.1%	0.0%
6 Months	-9.17%	5.1%	0.0%
1 Year	-27.18%	16.6%	0.0%
3 Years	-39.85%	13.2%	-21.4%

Highlights

Market Capitalization	17.6B
Book Value	$487.96
Earnings Per Share (EPS)	1.25
PE Ratio	22.02
PEG Ratio	0.96
Wall Street Target Price	39.7

Profit Margin	29.13%
Operating Margin TTM	33.62%

Return On Assets TTM	10.97%
Return On Equity TTM	18.55%

Revenue TTM	19.0B
Revenue Per Share TTM	29.21
Quarterly Revenue Growth YOY	29.599999999999998%
Gross Profit TTM	14.6B
EBITDA	6.5B
Diluted Eps TTM	1.25
Quarterly Earnings Growth YOY	0.07

EPS Estimate Current Year	1.17
EPS Estimate Next Year	1.5
EPS Estimate Current Quarter	0.33
EPS Estimate Next Quarter	0.34

Analyst Recommendation

Buy

61%Buy

29%Hold

9%Sell

Based on 31 Wall street analysts offering stock ratings for Genmab A/s(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 44.26%

Current $27.52

Target $39.70

Company Financials

	FY18	Y/Y Change
Revenue	461.0M	↑ 27.89%
Net Income	224.3M	↑ 33.4%
Net Profit Margin	48.66%	↑ 2.01%

	FY19	Y/Y Change
Revenue	798.0M	↑ 77.38%
Net Income	322.1M	↑ 47.13%
Net Profit Margin	40.37%	↓ 8.29%

	FY20	Y/Y Change
Revenue	1.7B	↑ 88.43%
Net Income	777.7M	↑ 119.67%
Net Profit Margin	47.06%	↑ 6.69%

	FY21	Y/Y Change
Revenue	1.3B	↓ 16.11%
Net Income	449.5M	↓ 37.85%
Net Profit Margin	34.86%	↓ 12.2%

	FY22	Y/Y Change
Revenue	2.1B	↑ 72.07%
Net Income	775.6M	↑ 84.38%
Net Profit Margin	37.36%	↑ 2.5%

	FY23	Y/Y Change
Revenue	2.4B	↑ 12.87%
Net Income	637.3M	↓ 20.18%
Net Profit Margin	26.42%	↓ 10.94%

	Q1 FY23	Q/Q Change
Revenue	410.2M	↓ 45.4%
Net Income	30.2M	↓ 64.04%
Net Profit Margin	7.36%	↓ 3.81%

	Q2 FY23	Q/Q Change
Revenue	611.0M	↑ 47.09%
Net Income	197.5M	↑ 546.19%
Net Profit Margin	32.32%	↑ 24.96%

	Q3 FY23	Q/Q Change
Revenue	679.2M	↑ 13.01%
Net Income	304.8M	↑ 56.89%
Net Profit Margin	44.88%	↑ 12.56%

	Q4 FY23	Q/Q Change
Revenue	685.1M	↓ 1.39%
Net Income	93.7M	↓ 69.94%
Net Profit Margin	13.68%	↓ 31.2%

	Q1 FY24	Q/Q Change
Revenue	787.4M	↑ 15.48%
Net Income	205.2M	↑ 120.0%
Net Profit Margin	26.06%	↑ 12.38%

	Q2 FY24	Q/Q Change
Revenue	779.3M	↑ 0.0%
Net Income	203.1M	↑ 0.0%
Net Profit Margin	26.06%	↑ 0.0%

	FY18	Y/Y Change
Total Assets	1.3B	↑ 28.14%
Total Liabilities	68.1M	↑ 35.04%

	FY19	Y/Y Change
Total Assets	2.3B	↑ 78.99%
Total Liabilities	163.0M	↑ 145.39%

	FY20	Y/Y Change
Total Assets	3.5B	↑ 39.61%
Total Liabilities	330.5M	↑ 84.49%

	FY21	Y/Y Change
Total Assets	3.7B	↑ 16.48%
Total Liabilities	369.5M	↑ 20.23%

	FY22	Y/Y Change
Total Assets	4.3B	↑ 22.95%
Total Liabilities	403.6M	↑ 16.7%

	FY23	Y/Y Change
Total Assets	5.2B	↑ 16.55%
Total Liabilities	538.8M	↑ 29.68%

	Q1 FY23	Q/Q Change
Total Assets	4.4B	↑ 0.38%
Total Liabilities	460.5M	↑ 12.94%

	Q2 FY23	Q/Q Change
Total Assets	4.7B	↑ 5.21%
Total Liabilities	469.1M	↑ 0.59%

	Q3 FY23	Q/Q Change
Total Assets	5.0B	↑ 10.19%
Total Liabilities	590.7M	↑ 28.02%

	Q4 FY23	Q/Q Change
Total Assets	5.2B	↑ 0.14%
Total Liabilities	538.8M	↓ 10.83%

	Q1 FY24	Q/Q Change
Total Assets	5.6B	↑ 9.44%
Total Liabilities	1.1B	↑ 107.94%

	Q2 FY24	Q/Q Change
Total Assets	5.6B	↑ 0.0%
Total Liabilities	1.1B	↑ 0.0%

	FY18	Y/Y Change
Operating Cash Flow	154.6M	↓ 36.14%
Investing Cash Flow	-270.9M	↑ 166.34%
Financing Cash Flow	-10.8M	↓ 132.99%

	FY19	Y/Y Change
Operating Cash Flow	197.2M	↑ 30.67%
Investing Cash Flow	-294.9M	↑ 11.53%
Financing Cash Flow	544.3M	↓ 5262.13%

	FY20	Y/Y Change
Operating Cash Flow	1.1B	↑ 385.14%
Investing Cash Flow	-384.3M	↑ 18.56%
Financing Cash Flow	11.6M	↓ 98.06%

	FY21	Y/Y Change
Operating Cash Flow	338.7M	↓ 65.37%
Investing Cash Flow	-146.1M	↓ 59.12%
Financing Cash Flow	-63.8M	↓ 691.55%

	FY22	Y/Y Change
Operating Cash Flow	556.5M	↑ 75.58%
Investing Cash Flow	-392.8M	↑ 187.3%
Financing Cash Flow	-112.2M	↑ 87.86%

	Q1 FY23	Q/Q Change
Operating Cash Flow	465.0M	↑ 712.81%
Investing Cash Flow	-263.7M	↑ 1249.26%
Financing Cash Flow	-87.8M	↓ 566.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	63.5M	↓ 86.52%
Investing Cash Flow	-267.1M	↑ 0.0%
Financing Cash Flow	1.0M	↓ 101.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	291.6M	↑ 367.2%
Investing Cash Flow	144.3M	↓ 154.93%
Financing Cash Flow	2.9M	↑ 185.71%

Technicals Summary

Sell

Neutral

Buy

Genmab A/s is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genmab A/s	1.66%	-9.17%	-27.18%	-39.85%	33.92%
Regeneron Pharmaceuticals, Inc.	1.63%	16.79%	36.21%	69.09%	305.56%
Novo Nordisk A/s	2.32%	-1.45%	34.23%	160.46%	417.73%
Alnylam Pharmaceuticals, Inc.	-8.76%	64.72%	22.51%	32.46%	198.44%
Vertex Pharmaceuticals Incorporated	0.44%	13.16%	36.42%	144.55%	167.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Genmab A/s	22.02	22.02	0.96	1.17	0.19	0.11	NA	487.96
Regeneron Pharmaceuticals, Inc.	29.93	29.93	1.54	45.05	0.17	0.08	NA	261.41
Novo Nordisk A/s	44.01	44.01	1.98	3.44	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.55	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.57	0.32	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genmab A/s	Buy	$17.6B	33.92%	22.02	29.13%
Regeneron Pharmaceuticals, Inc.	Buy	$124.7B	305.56%	29.93	32.04%
Novo Nordisk A/s	Buy	$585.3B	417.73%	44.01	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$32.3B	198.44%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$120.9B	167.72%	32.84	-4.74%

Insights on Genmab A/s

Increasing Revenue
Revenue is up for the last 3 quarters, 4.67B → 5.40B (in $), with an average increase of 6.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 640.0M → 1.40B (in $), with an average increase of 27.3% per quarter
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 63.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 144.6% return, outperforming this stock by 184.4%